Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
68.26
-3.19 (-4.46%)
At close: Apr 1, 2025, 4:00 PM
68.01
-0.25 (-0.37%)
After-hours: Apr 1, 2025, 4:47 PM EDT
Soleno Therapeutics Employees
Soleno Therapeutics had 92 employees as of December 31, 2024. The number of employees increased by 59 or 178.79% compared to the previous year.
Employees
92
Change (1Y)
59
Growth (1Y)
178.79%
Revenue / Employee
n/a
Profits / Employee
-$1,911,413
Market Cap
3.13B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SLNO News
- 5 days ago - Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder - Benzinga
- 5 days ago - Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome - GlobeNewsWire
- 2 months ago - Soleno Therapeutics to Participate in Upcoming February Investor Conferences - GlobeNewsWire
- 3 months ago - Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - GlobeNewsWire
- 4 months ago - Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 4 months ago - Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome - GlobeNewsWire
- 4 months ago - Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 - GlobeNewsWire
- 6 months ago - Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments - Seeking Alpha